ScholarWorks@SUNGKYUNKWAN UNIVERSITY: KIM, KYOUNG MEE

Detailed Information

KIM, KYOUNG MEE (김경미)

Medicine (Medicine)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Gastric cancer:32||gastric cancer:28||Stomach neoplasms:16||Prognosis:14||prognosis:12||Stomach:12||Early gastric cancer:11||Endoscopic submucosal dissection:10||PDL1:9||Pathology:8||gastric:8||carcinoma:8||immunotherapy:8||immunohistochemistry:8||Biomarker:7||biomarker:7||Immunohistochemistry:7||Nextgeneration sequencing:6||Gastrectomy:6||cancer:6||microsatellite instability:6||Carcinoma:5||Targeted therapy:5||HER2:5||nextgeneration sequencing:5||Lymph node metastasis:5||Diagnosis:5||EpsteinBarr virus:5||MET:5||Gastrointestinal stromal tumors:4||pathology:4||stomach:4||Biopsy:4||Mutation:4||KRAS:4||Survival:4||BRAF:4||Endoscopic resection:4||Guideline:4||gastrointestinal stromal tumor:4||Microsatellite instability:4||Gastric:4||Recurrence:4||Gastric carcinoma:4||methylation:4||Chemotherapy:3||Gastrointestinal stromal tumor:3||therapy:3||gastric carcinoma:3||Colorectal cancer:3||Neuroendocrine tumor:3||Immunotherapy:3||dysplasia:3||Gastrointestinal stromal tumour:3||Pembrolizumab:3||Sequencing:3||serrated adenoma:3||Melanoma:3||liquid biopsy:3||mutation:3||NGS:3||KIT mutation:3||Endoscopic mucosal resection:3||Adenoma:3||EGFR:3||Surgery:3||chemotherapy:3||BRAF mutation:2||Programmed deathligand 1:2||tumor microenvironment:2||tumor mutation burden:2||tumor mutational burden:2||in situ hybridization:2||RAD001:2||ATM:2||Dysplasia:2||lymph node metastasis:2||EBV:2||Molecular pathology:2||FGFR2:2||FGFR2 amplification:2||Cancer:2||metastasis:2||Regorafenib:2||microenvironment:2||DLL4:2||Helicobacter pylori:2||colon:2||colorectal cancer:2||colorectal carcinoma:2||multiple:2||ERBB2:2||Adenocarcinoma:2||CD274:2||Sarcopenia:2||Schwannoma:2||NanoString:2||Capecitabine:2||Neoplasms:2||Simvastatin:2||diagnosis:2||Neuroendocrine tumors:2||Next generation sequencing:2||Standardization:2||early gastric cancer:2||Stomach cancer:2||endoscopic submucosal dissection:2||Lymphoepitheliomalike gastric carcinoma:2||Subepithelial tumor:2||Sunitinib:2||GIST:2||Lymphomas:2||precursor:2||MAPK15:2||Target:2||PD1:2||Therapy:2||gastrointestinal neoplasms:2||gastrointestinal stromal tumour:2||risk factors:2||CD8:2||gene expression:2||Gastric neoplasms:2||Endoscopy:2||PTEN:2||Papillary adenocarcinoma:2||genomics:2||Pathology report:2||CDH1:2||squamous cell carcinoma:2||MerTK:2||Digital image analysis:2||Gastroscopy:2||Intraepithelial neoplasia:2||Prediction:2||surgery:2||survival:2||adenocarcinoma:2||BAT26:2||KIT:2||immune checkpoint inhibition:2||Epstein–Barr virus:2||Gastrointestinal tract:1||Gefitinib:1||Genes:1||Genome:1||Genomic analysis:1||Genomic test:1||Glomus tumor:1||Glycolysis:1||Guardant360:1||HIF2?:1||HRD:1||HSP90:1||Hamartoma:1||Hedgehog pathway:1||Helicobacter heilmannii:1||Hepatocyte growth factor:1||Hepatoid:1||Her2:1||Her2:1||Hereditary diffuse gastric cancer:1||Herpes zoster:1||Heterogeneity:1||Heterotopic gastric mucosa:1||Histological heterogeneity:1||Human epidermal growth factor 2 (HER2):1||Hyalinizing trabecular tumour:1||I mmunohistochemistry:1||IHC screen:1||IKK epsilon:1||Imatinib:1||Imatinib mesylate:1||Immune:1||Immune checkpoint inhibitors:1||Immune genes:1||Immunohistochemical stain:1||Immunoscore:1||Inci:1||Incidence:1||Indication:1||Indication of endoscopic submucosal dissection:1||Interaction:1||International Classification of Diseases:1||Intestine:1||Invasive breast cancer:1||Japanese:1||KIT amplificati:1||KIT amplification:1||KIT gene:1||Ketamine:1||Ki67:1||Kidney transplantation:1||Krukenberg:1||L cells:1||LAG3:1||LAG3:1||Lateral margin positivity:1||Lauren&apos:1||Leptomeningeal metastasis:1||Liver:1||Liver kinase B1:1||Liver metastasis:1||Loss of heterozygosity:1||Lymph node:1||Lymph nodes:1||Lymphadenopathy:1||Lymphangiectasia:1||Lymphatic invasion:1||Lymphoepitheliomalike carcinoma:1||Lymphoid cuff:1||Lymphoma:1||Lymphovascular invasion:1||Lynch syndrome:1||Lynchlike syndrome:1||MAD2:1||MEK:1||MET alterations:1||MET amplification:1||MET exon 14 skipping:1||MET kinase inhibitors:1||MET monoclonal antibodies:1||MGMT:1||MIB1:1||MSIH:1||MSS:1||Magnetic resonance imaging:1||Malakoplakia:1||Marginalzone Bcell lymphoma:1||Maximum tolerated dose:1||Metastasis:1||Metastatic cancer:1||Methylation:1||Methylation array:1||Microarray gene expression:1||Microcarcinoid:1||Microfluidic chip:1||Microsatellite instability:1||Microsatellite instabilityhigh:1||Microsatellite status:1||Mismatch repair deficiency:1||Mismatch repair protein:1||Mitosis:1||Mixed type:1||Molecular:1||Molecular biology:1||Molecular diagnosis:1||Molecular profiling:1||Molecular screening:1||Molecular subtype:1||Molecular subtyping:1||Monocarboxylate transporter:1||Mucin:1||Mucosal melanoma:1||Myofibroblasts:1||NMethylNnitrosoguanidine human osteosarcoma transforming gene (MET):1||NTRK:1||NTRK1 rearrangement:1||Nanostring:1||Neoadjuvant chemoradiotherapy:1||Neuroendocrine neoplasm:1||Neurofibroma:1||Nilotinib:1||Nivolumab:1||Nomogram:1||Noninvasive biomarkers:1||Nuclear segmentation:1||Observer variation:1||Oesophageal squamous cell carcinoma:1||Outcome:1||P:1||PARP:1||PCR:1||PDL1 expression:1||PDL1 score:1||PIK3CA mutation:1||PIK3CAE542K:1||PKCθ:1||PRO007:1||PTCH1:1||Pancreatic neuroendorcine tumors:1||Patientderived cell:1||Patientderived cells:1||Patientderived tumor spheroids:1||Pazopanib:1||Peritoneum:1||Pharmacogenomics:1||Platinum:1||Plexiform:1||Polymerase chain reaction:1||Precision:1||Predictive marker:1||Preoperative:1||Primary endoscopic submucosal dissection:1||Prog:1||Programmed cell death 1:1||Programmed death ligand 1:1||Programmed deathligand 1 (PDL1):1||RAS signature:1||RET fusion:1||RICTOR:1||RNF11:1||ROS1rearranged gastric adenocarcinoma:1||Radi:1||Radio:1||Radiotherapy:1||Ramucirumab:1||Realtime polymerase chai:1||Rectal neoplasms:1||Refractory gastric cancer:1||Reproducibility:1||Resection:1||Resistance mutation:1||Response:1||Ribonucleic acid sequencing:1||Risk factors:1||Risk grade:1||SAIT301:1||SLC34A2RO:1||SMO:1||Serine/threonine kinase 11:1||Serrated:1||Siewert type II/III:1||Signet ring cell carcinoma:1||Solid tumors:1||Somatostatin receptor 2:1||Splicing mutation:1||Squamous metaplasia:1||Stability:1||Stomach neoplasm:1||Sub:1||Submucosal tumor:1||Survival outcome:1||TBK1:1||TCGA molecular subtype:1||TERT promoter mutation:1||TMB:1||TP53 mutation:1||TPK1:1||TRAP:1||TRKA immunohistochemistry:1||Targeted sequencing:1||Termination assay:1||Thrombospondin1:1||Thy:1||Thyroid cytology:1||Treatment:1||Treatment strategy:1||TruSight™ Oncology 500 assay:1||Tumor immune microenvironment:1||Tumor mutation burden:1||Tumor stroma:1||Tumour mutation burden:1||Tyrosine kinase inhibitor:1||UB:1||Ultrastructure:1||Upper gastrointestinal series:1||Urothelial:1||Urothelial carcinoma:1||Vandetanib:1||Vascular endothelial growth factor:1||Vienna:1||Viral reactivation:1||WHO classification:1||WT1:1||Western:1||Wholeexome sequencing:1||adenoma:1||adjuvant:1||adjuvant chemotherapy:1||adjuvant therapy:1||alphamethylacylCoA racemase:1||ampullary adenoma:1||anaplastic lymphoma kinase (ALK) rearrangement:1||animal model:1||antiangiogenesis:1||apoptosis:1||ascites:1||automatic:1||big data:1||biopsy:1||blood transfusion:1||cJun:1||cMET:1||cMyc:1||ckit:1||cancer predisposition:1||cellfree DNA (cfDNA):1||cfDNA:1||chromogenic in situ hybridization:1||circulating tumor DNA:1||claudin 18.2:1||clinical trials, phase II as topic:1||coactivation:1||colitis:1||colorectal mucinous adenocarcinoma:1||combined immunodeficiency:1||combined positive score:1||computational biology:1||copy number alteration:1||copypaste:1||criteria:1||crizotinib:1||cutoff points:1||cyclin D1:1||cystic change:1||cytology:1||cytomegalovirus:1||deep learning:1||deletion:1||demography:1||digital image:1||digital pathology:1||digital sequencing:1||distant metastasis:1||duodenum:1||endoscopic biopsy:1||endoscopic mucosal resection:1||endoscopic resection:1||endoscopy:1||entrectinib:1||epidermal growth factor receptor mutation:1||epigenetic alternate promoter:1||esophageal neoplasm:1||esophagus:1||exosome:1||expression:1||familial:1||familial colon cancer:1||fibroblast growth factor receptor2:1||filiform:1||followup CT:1||frameshift mutation:1||gast:1||gastric polyp:1||gastritis:1||gastritis cystica profunda:1||gastrointestinal:1||gastrointestinal cancer:1||gastrointestinal malignancies:1||gastrointestinal tract:1||gene amplification:1||gene rearrangements:1||gene signature:1||genes, HER2:1||genetic diagnosis:1||genome instability:1||genomic:1||genomic test:1||germ cell tumor:1||glypican3:1||h:1||hMLH1:1||hamartomatous inverted polyp:1||hepatocellular carcinoma:1||hepatocyte growth factor:1||hepatoid carcinoma:1||highthroughput nucleotide sequencing:1||highthroughput s:1||histological heterogeneity:1||histology:1||human epidermal growth factor receptor 2:1||hyperplastic polyp:1||image augmentation:1||imatinib treatment:1||immune check point inhibitor:1||immune checkpoint blockade:1||immune checkpoint inhibitor:1||immune checkpoint inhibitors:1||immune infiltrates:1||immune microenvironment:1||immunohistochemical analysis:1||inactivation:1||inflammation:1||inflammatory bowel disease:1||intestine:1||intratumoral heterogeneity:1||inverted growth:1||inverted hyperplastic polyp:1||large:1||lymph node:1||lymphnode metastasis:1||lymphoma:1||lymphoma, mucosaassociated lymphoid tissue:1||mRNA expression:1||machine learning:1||malignancy:1||malignant:1||mastocytosis:1||mesenchymal:1||mesenchymal tumour:1||metastatic cancer:1||micropapillary:1||microsatellite stable:1||mismatch repair deficiency:1||mismatch repair deficiency (dMMR):1||molecular classification:1||mononucleotide repeat:1||mucinous:1||neuroendocrine tumors:1||neurofibromatosis:1||neversmoker:1||next generation sequencing:1||noninvasive cancer detection:1||nonsense mutation:1||oesophagus:1||oncogene:1||oncology:1||operation:1||orthotopic:1||ovary:1||ove:1||overall survival analysis:1||pmTOR:1||p12(DOC1):1||p16(INK4A):1||p53:1||p57:1||pSTAT3:1||pancreaticobiliary tract cancer:1||panel sequencing:1||paraganglioma:1||parietal cells, gastric:1||pathogenesis:1||patientderived cells:1||patientderived tumor cells:1||pazopanib:1||pembrolizumab:1||peritoneal seeding:1||pharmacodynamics:1||pharmacokinetics:1||phase I:1||polymerase:1||polymorphism:1||polyp:1||precision:1||precision medicine:1||prediction:1||primary immunodeficiency:1||prognostic marker:1||programmed cell death 1 receptor:1||programmed deathligand 1:1||programmed deathligand 1 (PDL1):1||pyloric gland adenoma:1||quality control:1||radial:1||radiation therapy:1||radiosensitivity:1||radiotherapy:1||realtime PCR:1||refractory cancer:1||regulation:1||remnant gastric cancer:1||resection margins:1||riskscoring system:1||s classification:1||s disease:1||s esophagus:1||sarcopenia:1||selumetinib:1||sequencing:1||serology:1||serra:1||sessile serrated adenoma:1||signet ring cell carcinoma:1||signetring cell:1||small extracellular vesicle:1||smallcell lung cancer:1||solid cancer:1||sporadic:1||stability:1||steroids:1||stomach cancer:1||stomach neoplasm:1||stomach neoplasms:1||stromal proliferation:1||subtypes:1||superficial spreading type:1||surfaceenhanced Raman spectroscopy (SERS):1||synchronous:1||target therapy:1||targeted therapy:1||telomerase:1||traditional serrated adenoma:1||transcriptome:1||triple negative breast cancer:1||tumor:1||tumor diameter:1||tumor location:1||tumor suppressor:1||tumor volume:1||type VII collagen (COL7A1):1||urothelial:1||zolbetuximab:1||권고안:1||암검진:1||위내시경:1||위암:1||AFP:1||위장조영촬영:1||ALK fusion:1||API2/MALT1:1||ARID1A:1||Acral melanoma:1||Adjuvant:1||Adjuvant chemoradiotherapy:1||Adjuvant therapy:1||Adjuvant treatment:1||Albumin:1||Amplification:1||Ampliseq:1||And vascular endothelial growth factor receptor 2 (VEGFR2):1||Angiogenesis:1||Angiogenesis signature:1||Angiomyxoid:1||Apoptosis:1||Apparent diffusion coefficient:1||Array comparative genomic hybridization:1||Ataxia telangiectasia mutated (ATM):1||B cell:1||B cells:1||Bcell:1||BRAFV600E mutation:1||Barrett oesophagus:1||Barrett&apos:1||Bevacizumab:1||Bif1 expression:1||Biochemistry:1||Biological marker:1||Biological sciences:1||Biomarkers:1||Breast neoplasm:1||CJun:1||CKIT mutation:1||CAT25:1||CCNE1:1||CD34:1||CD44:1||CISH:1||CMV:1||CT1b gastric cancer:1||CTLA4:1||CXCL13:1||Cancer immunotherapy:1||Capecitab:1||Carcinogenesis:1||Carney triad:1||Caspase:1||Castleman&apos:1||Cell biology:1||Cellfree DNA (cfDNA):1||Cerebellar tumor:1||Cerebrospinal fluid:1||Cetuximab:1||Checkpoint inhibitor:1||Chemotherapy, Targeted:1||Chief cells:1||Chordoid meningioma:1||Circulating tumor DNA:1||Circulating tumor cells:1||Cisplatin:1||Clear cell:1||Clinical trial:1||Clinical trials:1||Clinicopathologic
features:1||Colon:1||Colonic neoplasms:1||Colonic polyp:1||Colorectal cancer (CRC):1||Colorectal neoplasms:1||Colorectum:1||Comorbid disease:1||Comparison:1||Complication:1||Comprehensive cancer panel assay:1||Computed tomography:1||Concurrent chemoradiotherapy:1||Consensus:1||Conservative management:1||Copy number alteration:1||CpG island methylator phenotype:1||Criteria for expanded curative resection:1||Cyclin B1:1||Cyclin D1:1||Cyst:1||DNA:1||DNA damage:1||DNA methylation:1||DOG1:1||Dia:1||Diabetic gastropathy:1||Diagno:1||Differential diagnosis:1||Diffusion weighted imaging:1||Digestive system:1||Digital sequencing:1||Discrepancy:1||Diseasefree:1||Duodenal carcinoid tumor:1||Ecadherin:1||EBVpositive tumors:1||EGFR genes:1||EMT:1||ERBB2 mutation:1||ERCC1:1||Early detection of cancer:1||Electrophysi:1||En bloc plus R0 resection:1||En bloc resection:1||Endoscopic diagnosis:1||Endoscopic mucosal resection after circumferential precutting:1||Enteropathy:1||Epidermal growth factor receptor (EGFR):1||Epidural analgesia:1||Epithelialmesenchymal transition:1||Epstei:1||EpsteinBarr Virus:1||EpsteinBarr virusassociated gastric cancer:1||EpsteineBarr virus:1||Everolimus:1||FAP:1||FGFR2amplified:1||FLT3 amplification:1||FOXP3:1||Family history:1||Fine needle aspiration:1||Fluorescence in situ hybridization:1||Forceps biopsy:1||Frameshift mutation:1||Frozen section:1||Fundic gland:1||GAGE:1||GB:1||Gallbladder neoplasms:1||Gastric endoscopy:1||Gastric mucosal high grade neoplasia:1||Gastric mucosal low grade neoplasia:1||Gastroenteropancreatic neuroendocrine tumor:1||Gastroenteropancreatic neuroendocrine tumor (GEPNET):1||Gastrointestinal Stromal Tumors:1||Gastrointestinal submucosal tumor:1||

STATISTICS: Total View :5,219,861; Today View :1,111

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE